Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 6.12 Billion | USD 21.11 Billion | 13.42% | 2023 |
The global Neurological Biomarkers market size accrued earnings worth approximately USD 6.12 Billion in 2023 and is predicted to gain revenue of about USD 21.11 Billion by 2032, is set to record a CAGR of nearly 13.42% over the period from 2024 to 2032.
Neurological biomarkers are utilized for detecting the persons at the risk of having neurological ailments and some of these biomarkers are used for diagnosing the disorder, determine its progress, and estimate the disease result. In therapeutic surroundings, these biomarkers unleash information related to the effectiveness of the medicine for a particular neurological disorder as well as its side-effects. Citing an instance, uric acid is a key biomarker that helps in detecting the growth of Parkinson ailment and the need for the drug development to inhibit the growth. In addition to this, MRI-based biomarkers help in determining intensity of multiple sclerosis, spinal muscular atrophy, retinal neurodegenerative disorder, and acute ischemic strokes.
Technological innovations in genomics, metabolomics, and proteomics are predicted to steer the growth of neurological biomarkers industry over the estimated timeframe. Apparently, large-scale occurrence of the neurological ailments due to stressful & hectic work schedule as well as work-life imbalance will drive the market trends. In addition to this, less proportion of effective diagnostics tools available in emerging countries has resulted in rise in the mortality due to neurological diseases, thereby enhancing the need for neurological biomarkers in these countries.
Furthermore, surge in the neurological disorders like Alzheimer, brain tumors, Parkinson, cerebral stroke, and epilepsy will pave a way for the industry growth over the forecasting years. Apparently, favorable government schemes as well as rise in the investment in neurological diagnostics sector has translated into market demand. Rise in the research activities pertaining to neuroscience and huge funding provided by the government agencies to promote neuro-medicine discoveries will embellish the industry expansion in the coming years.
Report Attributes | Report Details |
---|---|
Report Name | Neurological Biomarkers Market |
Market Size in 2023 | USD 6.12 Billion |
Market Forecast in 2032 | USD 21.11 Billion |
Growth Rate | CAGR of 13.42% |
Number of Pages | 204 |
Key Companies Covered |
Bio-Rad Laboratories, Inc., QIAGEN, Alseres Pharmaceuticals, Inc., Abbott, Thermo Fisher Scientific Inc., Acumen Pharmaceuticals, Myriad RBM, Athena Diagnostics; AbaStar MDx, Inc., and BANYAN BIOMARKERS, INC |
Segments Covered | By Application, By Type, By End-user, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
Product type, indication, imaging methods, services, and end user are the factors that divide the market for neurological biomarkers. The expansion within these sectors will assist in examining areas of limited growth within the industries and offer users a valuable market overview and insights to aid in making strategic decisions for identifying key market applications.
Asia Pacific Market To Accrue Huge Returns Over 2024-2032
Rise in the occurrence of neurological disorders like Alzheimer and Parkinson among the aging population has generated huge demand for the neurological biomarker, thereby spurring the market growth in the region. Apart from this, rise in the awareness pertaining to neurological diseases and a complete overhaul as well as drastic improvisations witnessed in healthcare infrastructure facilities in the countries like China will magnify the market growth in the Asia Pacific zone. Apart from China, countries like South Korea and India are projected to be the major regional revenue drivers over the next couple of years.
Key players influencing the market growth are
By application:
By type:
By end-user:
By Region
FrequentlyAsked Questions
Technological innovations in genomics, metabolomics, and proteomics are predicted to steer the growth of neurological biomarkers industry over the estimated timeframe.
The CAGR of the industry is expected to be nearly 13.42% during the forecast timespan.
Asia Pacific region will contribute sizably towards the global market revenue over the estimated timeline.
The key market participants include Bio-Rad Laboratories, Inc., QIAGEN, Alseres Pharmaceuticals, Inc., Abbott, Thermo Fisher Scientific Inc., Acumen Pharmaceuticals, Myriad RBM, Athena Diagnostics; AbaStar MDx, Inc., and BANYAN BIOMARKERS, INC.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed